ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.

被引：0
|
作者：
Olawaiye, Alexander
Monk, Bradley J.
Herzog, Thomas J.
Copeland, Larry J.
Coleman, Robert L.
Moore, Kathleen N.
Randall, Leslie M.
Slomovitz, Brian M.
O'Malley, David M.
Eskander, Ramez Nassef
Pothuri, Bhavana
Van Gorp, Toon
Pignata, Sandro
Nicum, Shibani
Tudor, Iulia Cristina
Nguyen, Dorothy D.
Lorusso, Domenica
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Creighton Univ Sch Med, Univ Arizona Coll Med, GOG Fdn, Phoenix, AZ USA
[3] Univ Cincinnati Canc Inst, Cincinnati, OH USA
[4] Ohio State Univ, James Canc Ctr, Columbus, OH USA
[5] US Oncol Res, Spring, TX USA
[6] Univ Oklahoma HSC, Stephenson Canc Ctr, Oklahoma City, OK USA
[7] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[8] Florida Int Univ, Mt Sinai Med Ctr, Miami Beach, FL USA
[9] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA
[10] Moores Canc Ctr, La Jolla, CA USA
[11] NYU Grossman Sch Med, Perlmutter Canc Ctr, NYU Langone Hlth, Ney York, NY USA
[12] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[13] Ist Nazl Tumori Napoli, Naples, Italy
[14] Univ Coll London Canc Inst, London, England
[15] Corcept Therapeut, Menlo Pk, CA USA
[16] Catholic Univ, IRCCS, Sacred Heart & Fondazione Policlinico Gemelli, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5620
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase Ib study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
    Fu, S.
    Corr, B.
    Hamilton, E.
    Burger, R. A.
    Wenham, R.
    Naumann, R. W.
    Stagg, R.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial
    Yuan, Guangwen
    Zhang, Keqiang
    Zheng, Hong
    Wu, Yan
    Sun, Haolin
    Zhang, Jiajing
    Sun, Xiyang
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2024, 187 : 212 - 220
  • [43] Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer
    Colombo, Nicoletta
    Van Gorp, Toon
    Matulonis, Ursula
    Oaknin, Ana
    Grisham, Rachel
    Provencher, Diane
    Fleming, Gini
    Olawaiye, Alexander
    Pashova, Hristina
    Tudor, Iulia Cristina
    Dreiling, Lyndah
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S74 - S74
  • [44] Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
    Colombo, N.
    Nguyen, D. D.
    Fleming, G. F.
    Grisham, R. N.
    Lorusso, D.
    Van Gorp, T.
    Oaknin, A.
    Pashova, H. I.
    Grauer, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S725 - S725
  • [45] Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
    Xia, L.
    Zhou, Q.
    Zhang, Y.
    Gao, Y.
    Hu, W.
    Pan, M.
    Lou, G.
    Wang, L.
    Shi, H.
    Zhu, J.
    Sun, H.
    Wang, X.
    Wang, Q.
    Wu, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S630
  • [46] ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)
    Herzog, Thomas J.
    Hays, John L.
    Barlin, Joyce N.
    Buscema, Joseph
    Cloven, Noelle Gillette
    Kong, Lynn R.
    Tyagi, Nidhi Kumar
    Lanneau, Grainger
    Long, Beverly J.
    Marsh, Robert L.
    Seward, Shelly Marie
    Starks, David
    Welch, Stephen
    Moore, Kathleen N.
    Konstantinopoulos, Panagiotis A.
    Gilbert, Lucy
    Monk, Bradley J.
    O'Malley, David M.
    Coleman, Robert L.
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] ARTISTRY-7: A PHASE 3, MULTICENTER STUDY OF NEMVALEUKIN ALFA IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (GOG-3063; ENGOT-OV68)
    Sehouli, Jalid
    Hays, John L.
    Barlin, Joyce N.
    Buscema, Joseph
    Cloven, Noelle G.
    Kong, Lynn R.
    Tyagi, Nidhi Kumar
    Lanneau, Grainger S.
    Long, Beverly J.
    Marsh, Robert L.
    Seward, Shelly M.
    Starks, David C.
    Welch, Stephen
    Moore, Kathleen N.
    Konstantinopoulos, Panagiotis A.
    Gilbert, Lucy
    Monk, Bradley J.
    O'Malley, David M.
    Coleman, Robert L.
    Herzog, Thomas J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A416 - A416
  • [48] A phase 3 study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman, Robert L.
    Monk, Bradley J.
    del Carmen, Marcela G.
    Knoblauch, Roland Elmer
    Parekh, Taal V.
    Dawkins, Fitzroy W.
    Maul, Raymond Scott
    Park, Youn Choi
    Herzog, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Prevalence study of germline BRCA1/2 mutation in Korean patients with high-grade serous and/or endometrioid epithelial ovarian, Fallopian tube, or primary peritoneal cancer.
    Heo, Eun Jin
    Kim, Byoung
    Choi, Chel Hun
    Lee, Jeong-Won
    Lee, Yoo-Young
    Kim, Yong-Man
    Kim, Jong-Won
    Song, Sang-Yong
    Kim, Jae Weon
    Kim, Jae Hoon
    Kang, Sokbom
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer (EOC): The SIERRA multi-institutional open-label phase Ib trial
    Handley, K. F.
    Moore, K. N.
    Burger, R. A.
    Dal Molin, G. Z.
    Stagg, R.
    Sood, A. K.
    Coleman, R. L.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 14 - 14
12345